Abstract

BackgroundHereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is a rare disease. Few states in developing countries have an adequate management of HAE, but none of them belongs to the former USSR area. This study analyses data from C1-INH-HAE patients from Belarus.MethodsData about clinical characteristics, genetics, access to diagnosis and treatment were collected from 2010 by the Belarusian Research Center for Pediatric Oncology, Hematology and Immunology in Minsk. A questionnaire about attacks, prophylactic (LTP) and on-demand therapy (ODT) was administered to patients.ResultsWe identified 64 C1-INH-HAE patients belonging to 26 families, 27 (42.2%) of which were diagnosed in the last 3 years. The estimated minimal prevalence was 1:148,000. Median age at diagnosis was 29 years, with diagnostic delay of 19 years. Thirty-eight patients answered a questionnaire about therapy. Eleven patients did not use any treatment to resolve HAE attacks. Twenty-seven patients underwent ODT: 9 with appropriate treatments, and 18 with inappropriate treatments. Nine patients used LTP with attenuated androgens and 1 with tranexamic acid. Thirty-two patients answered a questionnaire about attacks and triggers: 368 angioedema attacks were reported, with an average of 10 attacks per year. We found 24 different SERPING1 variants: 9 missenses, 6 in splice sites, 6 small deletions, 2 nonsense, 1 large deletion; 7 have not been previously described. De novo variants were found in 11 patients.ConclusionsC1-INH-HAE diagnosis and management in Belarus is improved as seen from the high number of new diagnosis in the last 3 years. Next steps will be to reduce the diagnostic delay and to promote the LTP and ODT.

Highlights

  • Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is a rare disease

  • Epidemiology and access to diagnosis We identified 64 C1 Inhibitor (C1-INH)-HAE patients (39 female): 54 were type I (84.4%) and 10 type II (15.6%)

  • Poor clinical awareness can contribute to the low diagnostic rate of HAE and may be a confounder in ascertaining true national prevalence

Read more

Summary

Introduction

Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is a rare disease. Hereditary angioedema (HAE) due to C1 Inhibitor (C1-INH) deficiency (C1-INH-HAE) is a rare autosomal dominant disease caused by reduced C1-INH plasma levels (C1-INH-HAE type I) or by the presence of a dysfunctional C1-INH (C1-INH-HAE type II) [1]. C1-INHHAE type I is estimated to occur in approximately 85% of cases, type II occurs in the remaining 15%. Data on the prevalence of C1-INH-HAE are sparse. Lower rate is reported in Greece [14], Serbia [18], Slovenia [19], and Spain [20], where the prevalence has been evaluated to be approximately 1:90,000 to 1:105,000 inhabitants

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call